4-[4-(2-Carbamoylpyridin-4-yl)oxy-3-fluoroanilino]-2-methylsulfanylpyrimidine-5-carboxylic acid | 931204-15-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[4-(2-Carbamoylpyridin-4-yl)oxy-3-fluoroanilino]-2-methylsulfanylpyrimidine-5-carboxylic acid
• CAS: 931204-15-8
• 化学式: C₁₈H₁₄FN₅O₄S
• 分子量: 415.405
• InChiKey: LJAODDMBTOXHRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  166
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  4-[4-(2-Carbamoylpyridin-4-yl)oxy-3-fluoroanilino]-2-methylsulfanylpyrimidine-5-carboxylic acid 在 氯化亚砜 作用下， 生成
  参考文献：
  名称：

  Design, synthesis and structure–activity relationships of novel biarylamine-based Met kinase inhibitors

  摘要：

  Biarylamine-based inhibitors of Met kinase have been identified. Lead compounds demonstrate nanomolar potency in Met kinase biochemical assays and significant activity in the Met-driven GTL-16 human gastric carcinoma cell line. X-ray crystallography revealed that these compounds adopt a bioactive conformation, in the kinase domain, consistent with that previously seen with 2-pyridone-based Met kinase inhibitors. Compound 9b demonstrated potent in vivo antitumor activity in the GTL-16 human tumor xenograft model. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.042
• 作为产物：
  描述：

  ethyl 4-(4-(2-carbamoylpyridin-4-yloxy)-3-fluorophenylamino)-2-(methylthio)pyrimidine-5-carboxylate 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 以83%的产率得到4-[4-(2-Carbamoylpyridin-4-yl)oxy-3-fluoroanilino]-2-methylsulfanylpyrimidine-5-carboxylic acid
  参考文献：
  名称：

  Design, synthesis and structure–activity relationships of novel biarylamine-based Met kinase inhibitors

  摘要：

  Biarylamine-based inhibitors of Met kinase have been identified. Lead compounds demonstrate nanomolar potency in Met kinase biochemical assays and significant activity in the Met-driven GTL-16 human gastric carcinoma cell line. X-ray crystallography revealed that these compounds adopt a bioactive conformation, in the kinase domain, consistent with that previously seen with 2-pyridone-based Met kinase inhibitors. Compound 9b demonstrated potent in vivo antitumor activity in the GTL-16 human tumor xenograft model. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.042

文献信息

• MET kinase inhibitors
  申请人：Borzilleri M. Robert

  公开号：US20070078140A1

  公开（公告）日：2007-04-05

  The present invention is directed to compounds having the formula I or II: including salts thereof, and methods for using them for the treatment of cancer.

  本发明涉及具有以下化学式I或II的化合物：包括其盐，并且使用它们用于治疗癌症的方法。
• US7547782B2
  申请人：——

  公开号：US7547782B2

  公开（公告）日：2009-06-16